Monoclonal antibodies against NRP1 have an additive effect with anti-VEGF therapy to inhibit the growth of non-small cell lung cancer (NSCLC) xenografts in mice [51]. This evidence concerns the gene VEGFA and non-small cell lung carcinoma.